Capricor Therapeutics (CAPR) EBIAT: 2011-2025
Historic EBIAT for Capricor Therapeutics (CAPR) over the last 13 years, with Sep 2025 value amounting to -$24.6 million.
- Capricor Therapeutics' EBIAT fell 95.68% to -$24.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$68.6 million, marking a year-over-year decrease of 101.20%. This contributed to the annual value of -$40.5 million for FY2024, which is 81.57% down from last year.
- As of Q3 2025, Capricor Therapeutics' EBIAT stood at -$24.6 million, which was down 0.73% from -$24.4 million recorded in Q2 2025.
- In the past 5 years, Capricor Therapeutics' EBIAT ranged from a high of -$762,089 in Q4 2023 and a low of -$24.6 million during Q3 2025.
- In the last 3 years, Capricor Therapeutics' EBIAT had a median value of -$8.8 million in 2023 and averaged -$11.2 million.
- Per our database at Business Quant, Capricor Therapeutics' EBIAT surged by 90.13% in 2023 and then slumped by 833.83% in 2024.
- Over the past 5 years, Capricor Therapeutics' EBIAT (Quarterly) stood at -$6.2 million in 2021, then declined by 24.72% to -$7.7 million in 2022, then surged by 90.13% to -$762,089 in 2023, then tumbled by 833.83% to -$7.1 million in 2024, then plummeted by 95.68% to -$24.6 million in 2025.
- Its EBIAT stands at -$24.6 million for Q3 2025, versus -$24.4 million for Q2 2025 and -$7.1 million for Q4 2024.